Back

18-21 AMAZE-lung

Details

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI.

AMAZE-lung: Amivantamab, lazertinib and bevacizumab in patients with EGFR-mutant advanced non-small cell lung cancer with progression on previous third-generation EGFR-TKI

The AMAZE-lung study aims to test the efficacy of amivantamab, bevacizumab and lazertinib in patients with EGFR-mutant advanced NSCLC.

Trial Scheme

Trial Information

Primary Endpoint:
Objective response rate (ORR), investigator assessed, at 12 weeks according to RECIST v1.1.
Secondary Endpoints:
Duration of response
Progression-free survival
Disease control rate
Overall survival
Safety and tolerability
Target Sample Size:
60 patients
Final Accrual
61 patients
Protocol Release Date:
14 September 2022
Trial Activation Date:
14 March 2022
First Patient In:
27 March 2022

Trial Organisation

Trial Chair:
Ross Soo, Singapore
Trial Co-Chair:
Sanjay Popat, London, United Kingdom
Sponsor:
ETOP IBCSG Partners Foundation
Coordinating Group:
ETOP IBCSG Partners Foundation
Participating Groups:
Swiss Group for Clinical Cancer Research (SAKK), Spanish Lung Cancer Group (SLCG) 
Participating Countries:
France, Italy, Netherlands, Spain, Switzerland, United Kingdom
Registrations:
EudraCT number: 2021-002337-42
clinicaltrials.gov: NCT05601973

Contact

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland
AMAZE-lung@etop.ibcsg.org

Log in to gain access to trial related material.

Log in